Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG Article

Blumenthal, Deborah T, Gorlia, Thierry, Gilbert, Mark R et al. (2017). Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG . NEURO-ONCOLOGY, 19(8), 1119-1126. 10.1093/neuonc/nox025

Open Access International Collaboration

cited authors

  • Blumenthal, Deborah T; Gorlia, Thierry; Gilbert, Mark R; Kim, Michelle M; Nabors, L Burt; Mason, Warren P; Hegi, Monika E; Zhang, Peixin; Golfinopoulos, Vassilis; Perry, James R; Nam, Do Hyun; Erridge, Sara C; Corn, Benjamin W; Mirimanoff, Rene O; Brown, Paul D; Baumert, Brigitta G; Mehta, Minesh P; van den Bent, Martin J; Reardon, David A; Weller, Michael; Stupp, Roger

sustainable development goals

authors

publication date

  • August 1, 2017

webpage

published in

keywords

  • BEVACIZUMAB
  • Clinical Neurology
  • INDUCTION
  • Life Sciences & Biomedicine
  • MALIGNANT GLIOMAS
  • MOLECULAR-MECHANISMS
  • Neurosciences & Neurology
  • OPEN-LABEL
  • Oncology
  • RADIOTHERAPY
  • RANDOMIZED PHASE-III
  • RESISTANCE
  • STANDARD TREATMENT
  • Science & Technology
  • TOXICITY

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 1119

end page

  • 1126

volume

  • 19

issue

  • 8